# Perspective Therapeutics, Inc.: overview CATX · NYSE · CIK 728387 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/catx.md) · [Financials](/companies/catx/financials.md) · [Filings](/companies/catx/filings.md) · [Insiders](/companies/catx/insiders.md) Latest reported revenue: [−$4.9m](/filings/0001437749-24-009696.md) for Q4 FY2023, three months to 2023-12-31, from the 10-K filed Mar 28, 2024 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-24-009696). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.21)](/filings/0001193125-25-274328.md) | not reported | [(0.25)](/filings/0001193125-26-216790.md) | [(0.29)](/filings/0001193125-26-342512.md) | [(0.35)](/filings/0001193125-25-274328.md) | not reported | [(0.25)](/filings/0001193125-26-216790.md) | [(0.22)](/filings/0001193125-26-342512.md) | | Free cash flow | $m | [(26.3) d](/filings/0001193125-25-274328.md) | [(41.2) d](/filings/0000728387-26-000004.md) | [(26.2)](/filings/0001193125-26-216790.md) | [(21.0) d](/filings/0001193125-26-342512.md) | [(18.3) d](/filings/0001193125-25-274328.md) | [(29.7) d](/filings/0000728387-26-000004.md) | [(38.3)](/filings/0001193125-26-216790.md) | [(34.8) d](/filings/0001193125-26-342512.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [10.8](/filings/0001437749-23-011946.md) | [0.0](/filings/0001437749-24-009696.md) | [1.4](/filings/0001437749-24-009696.md) | not reported | not reported | | Gross margin | % | [0.0%](/filings/0001437749-24-009696.md) | not reported | [100.0%](/filings/0001437749-24-009696.md) | not reported | not reported | | Operating margin | % | [(59.5%)](/filings/0001437749-24-009696.md) | not reported | [(2855.0%)](/filings/0000950170-25-046758.md) | not reported | not reported | | Net margin | % | [(67.4%)](/filings/0001437749-24-009696.md) | not reported | [(3243.2%)](/filings/0000950170-25-046758.md) | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | [(1.74)](/filings/0000950170-25-046758.md) | [(1.23)](/filings/0000728387-26-000004.md) | [(1.40)](/filings/0000728387-26-000004.md) | | Free cash flow | $m | [(8.0)](/filings/0001437749-24-009696.md) | [(10.7)](/filings/0001437749-24-009696.md) | [(38.0)](/filings/0000950170-25-046758.md) | [(72.7)](/filings/0000728387-26-000004.md) | [(95.2)](/filings/0000728387-26-000004.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/catx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $32.4m | 9,494,152 | | Added +4,145,591 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $27.0m | 7,915,567 | | Unchanged | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $21.6m | 6,336,782 | | Unchanged | | [Avidity Partners Management LP](/funds/1791827.md) | 2026-06-30 | $21.5m | 6,299,999 | | Added +250,000 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $20.6m | 6,051,771 | | Added +2,919,101 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $16.7m | 4,911,855 | | Added +865,215 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $15.1m | 4,436,572 | | Added +57,616 | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $14.4m | 4,214,582 | | Added +1,050,000 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $13.0m | 3,805,739 | | Added +239,235 | | [Spruce Street Capital LP](/funds/2050194.md) | 2026-06-30 | $12.6m | 3,693,931 | | Added +1,066,824 | ## Recent filings [All 876 filings](/companies/catx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 10:52 ET | [8-K](/filings/0001193125-26-429770.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429770 | | 2026-10-08 | 10:28 ET | [8-K](/filings/0001193125-26-417384.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-417384 | | 2026-10-01 | 20:08 ET | [8-K](/filings/0001193125-26-410663.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-410663 | | 2026-09-23 | 16:19 ET | [SCHEDULE 13D/A](/filings/0001193125-26-399446.md) | Ownership report, active investor, amended | 0001193125-26-399446 | | 2026-09-14 | 10:20 ET | [8-K](/filings/0001193125-26-389785.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-389785 | | 2026-09-08 | 21:16 ET | [8-K](/filings/0001193125-26-385362.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-385362 | | 2026-09-04 | 16:48 ET | [SCHEDULE 13D/A](/filings/0001193125-26-383775.md) | Ownership report, active investor, amended | 0001193125-26-383775 | | 2026-08-10 | 20:34 ET | [10-Q](/filings/0001193125-26-342512.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342512 | | 2026-08-10 | 20:30 ET | [8-K](/filings/0001193125-26-342495.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-342495 | | 2026-08-03 | 20:15 ET | [8-K](/filings/0001193125-26-330599.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-330599 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000728387-26-000004.md), filed Mar 16, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 728387 - Tickers: CATX - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.